The United States faces a critical moment in its technological future as it risks falling behind in the global competition for leadership in artificial intelligence (AI) and biotechnology. Policymakers in Washington have recognized the importance of AI, yet they have not adequately prepared for its convergence with biotechnology, a fusion that is expected to define economic and national power in the coming decades. The current state of the U.S. biodata environment is fragmented, underfunded, and insecure, posing a significant threat to national interests.
The National Security Commission on Emerging Biotechnology has emphasized that the future of biotechnology will hinge on controlling the most complete, accurate, and secure biological datasets. These datasets, which include DNA, RNA, proteins, and metabolites, are crucial for innovation in various sectors, including healthcare, agriculture, and industrial production. Without a federally led initiative to develop AI-ready biodata, the U.S. risks ceding leadership to competitors, particularly China.
The Strategic Importance of AI-Enabled Biotechnology
AI can significantly enhance biotechnology, providing solutions from bio-based materials for military applications to domestic biomanufacturing capabilities that mitigate supply chain vulnerabilities. However, the binding constraint remains the availability of large, representative biological datasets. The U.S. must improve its access to such biodata to harness the full potential of AI-driven biotechnology.
China, in particular, is rapidly advancing in this domain. The Chinese government has strategically linked biotechnology, big data, and AI, creating a coordinated ecosystem that supports data generation and industrial translation. For instance, the domestic non-invasive prenatal testing market in China was valued at approximately $608 million in 2023 and is expected to exceed $1 billion by the end of the decade. Companies like BGI Group are at the forefront, utilizing integrated platforms to generate and process vast amounts of genomic data.
The Chinese model of centralized data management allows for seamless integration of diverse datasets, enabling efficient training of AI models. By contrast, the U.S. biodata repositories, while world-class, are often designed for archival access rather than coordinated industrial application. This lack of integration hinders the U.S. from fully leveraging its existing data resources.
Challenges Facing U.S. Biodata Infrastructure
The United States currently faces significant challenges in its biodata ecosystem. Issues of data diversity, quality, interoperability, and security undermine the potential for developing a competitive AI-bio ecosystem. For instance, many foundational genomic datasets are disproportionately composed of individuals of European ancestry, which limits the generalizability of AI models across diverse populations.
Moreover, biological datasets often suffer from inconsistencies in annotation and collection methods, leading to noisy data that compromises analytical performance. Even high-quality data becomes less valuable if it cannot be integrated effectively across various systems and applications. The lack of interoperability among biomedical repositories complicates cross-domain analysis and increases costs.
Security is another pressing concern. As biodata systems grow in complexity, they become attractive targets for cyber threats. The fragmentation of the U.S. biodata environment does not eliminate these risks; it simply diffuses accountability, making it challenging to secure sensitive information.
To address these challenges, U.S. policymakers must take decisive action. The National Security Commission on Emerging Biotechnology has indicated that the U.S. has a limited window—around three years—to reassert its leadership in biotechnology. This necessitates a focused strategy for building AI-ready biodata infrastructure.
Investments in large, longitudinal datasets, standardized metadata, and secure governance frameworks are essential. Congress should direct relevant agencies, such as the Department of Energy and the National Institutes of Health, to fund the development of AI-ready biodata as critical national infrastructure.
The path forward requires a national strategy that aligns public investments with private sector innovation. While private firms can drive data generation, they often focus on proprietary datasets, leaving significant gaps in public-interest data necessary for national security and long-term competitiveness.
A coordinated approach would involve creating a secure national compute-to-data portal that allows vetted users to access sensitive datasets while ensuring privacy and security. This model would facilitate the integration of AI with biodata without compromising sensitive information.
As the landscape of biotechnology continues to evolve, the stakes are high. The nation that leads in AI-enabled biology will shape global standards and influence various sectors, from healthcare to climate resilience. The U.S. must act swiftly to invest in the biodata infrastructure that will define the future of biotechnology. Without substantial and strategic investment, America risks becoming dependent on foreign-controlled supply chains for crucial bioindustrial resources, jeopardizing both its economic stability and national security.
The urgency of the situation is clear. The United States has the opportunity to lead, but it requires immediate action to build the necessary biodata and infrastructure to secure its position in the biotechnology landscape of the 21st century.
